Massive immediate dilution: the ~42.8M new shares will hit the market and crush EPS. The stock trades on OTCQB with thin liquidity — expect significant downward pressure as former preferred holders likely convert to common and sell. Monitor for any subsequent S-1 filing registering these shares for resale.
Price Chart
Executive Summary
Galera Therapeutics converted its remaining 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,839,103 shares of common stock on May 15, 2026. This mandatory conversion eliminates all outstanding preferred shares, but massively dilutes existing common shareholders by more than doubling the share count — a clearly negative event for current holders.
Key Facts
- Remaining 42,839.11 Series B Preferred shares converted into 42,839,103 common shares on May 15, 2026.
- No fractional shares issued; cash paid in lieu of fractions per certificate of designation.
- Following conversion, zero Series B Preferred shares remain outstanding.
- Share count increased by ~42.8 million shares — a massive dilution event for a micro-cap biotech trading on OTCQB.
Financial Impact
42,839,103 newly issued common shares. Prior to this conversion, the company had approximately 7.2 million shares outstanding as of the most recent 10-Q, so this represents roughly a 600% increase in share count. No dollar value was stated.
Risk Factors
- Massive dilution — share count increased by ~600%, severely depresses EPS and book value per share.
- Potential selling pressure from former preferred holders now holding freely tradable common stock.
- The conversion signals the company has little equity cushion left; no preferred capacity remaining for future financing.
- Biotech trading on OTCQB with no analyst bullish sentiment (0% bullish) faces existential risk if pipeline fails.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-230711 |
| Document: 0001193125-26-230711-index-headers.html | 0001193125-26-230711 |
| Document: 0001193125-26-230711-index.html | 0001193125-26-230711 |
| Document: 0001193125-26-230711.txt | 0001193125-26-230711 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 11w ago | EFFECT | — | awaiting T+20 | — | — |
Aug 4, 2026 11w ago | 15-12G | — | awaiting T+20 | — | — |
Aug 3, 2026 11w ago | 8-K | — | awaiting T+20 | — | — |
Jul 13, 2026 15w ago | 8-K | $16.39 | awaiting T+20 | — | — |
Jul 7, 2026 15w ago | 8-K | $17.80 | awaiting T+20 | — | — |
May 21, 2026 22w ago | 425 | $0.1000 $0.0910 | ▼ −9.00% | ▼ −7.58% | — |
May 19, 2026 22w ago | 8-K | $0.1010 $0.0857 | ▲ +15.15% | ▲ +15.89% | — |
Apr 22, 2026 26w ago | 425 | $20.00 $20.20 | ▲ +1.00% | ▼ −3.22% | — |
Apr 22, 2026 26w ago | 425 | $20.00 $20.20 | ▲ +1.00% | ▼ −3.22% | — |
Apr 14, 2026 27w ago | Press Release | $0.0790 $0.1000 | ▼ −26.58% | ▼ −20.29% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers